Ewing Sarcoma in Nepal Treated With Combined Chemotherapy and Definitive Radiotherapy.

Autor:	Jha AK; BP Koirala Memorial Cancer Hospital, Bharatpur, Nepal., Neupane P; BP Koirala Memorial Cancer Hospital, Bharatpur, Nepal., Pradhan M; Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Sharma KS; BP Koirala Memorial Cancer Hospital, Bharatpur, Nepal., Shrestha S; BP Koirala Memorial Cancer Hospital, Bharatpur, Nepal., Sigdel PR; BP Koirala Memorial Cancer Hospital, Bharatpur, Nepal., Smeland S; Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Bruland ØS; Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Jazyk:	angličtina
Zdroj:	Journal of global oncology [J Glob Oncol] 2019 Mar; Vol. 5, pp. 1-10.
DOI:	10.1200/JGO.19.00015
Abstrakt:	Purpose: To our knowledge, we conducted the first prospective oncologic clinical trial in Nepal aimed at providing state-of-the-art chemotherapy to patients with Ewing sarcoma. The efficacy of external-beam radiotherapy (RT) as the sole local treatment modality was explored and deemed justified as a result of the lack of available advanced tumor-orthopedic services in Nepal. Patients and Methods: Twenty patients, 11 female and 9 male patients between the ages of 6 and 37 years, with newly diagnosed Ewing sarcoma were enrolled. Neoadjuvant combination chemotherapy, comprising well-established drug combinations, was administered in five courses before external-beam RT, during which one course of etoposide and ifosfamide was given. After RT, six additional chemotherapy courses were scheduled. Results: RT was tolerated well, providing rapid symptom relief and local tumor control, with no pathologic fractures observed among the 15 patients who received such treatment. Eleven patients completed the entire treatment protocol; seven patients were under continued follow-up, with no evidence of disease in six patients at a median follow-up time of 2.3 years (range, 1.3 to 3.1 years) and one patient alive but with a regional recurrence. Four patients experienced metastatic relapse and died as a result of their disease. Three treatment-related deaths linked to toxicity from chemotherapy occurred. Four of the six patients who refused to complete the treatment protocol and were lost to follow-up experienced progressive disease and were assumed dead. Conclusion: This study was feasible with RT as the sole local treatment modality in combination with chemotherapy. As a result of the high number of patients lost to follow-up, no firm conclusions can be drawn, but the majority of the patients who completed treatment obtained durable long-term remissions.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu